Oppenheimer & Close’s Moderna MRNA Stock Holding History

Oppenheimer & Close’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-885	Closed	-$207K	–	67
2021 Q2	$207K	Buy	+885	New	+$158K	0.19%	56

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Oppenheimer & Close's MRNA Position: Q3 2021 in Review

Oppenheimer & Close sold out of Moderna (MRNA) in Q3 2021, closing a stake of 885 shares — an estimated $207K sold.

Oppenheimer & Close first reported a position in MRNA in Q2 2021 and held it in 1 quarter. The position peaked at $207K in Q2 2021. 1,140 funds tracked by Wall St. Rank hold MRNA as of Q3 2021.

Oppenheimer & Close reported no remaining Moderna position as of Q3 2021 after selling out during the quarter.
Oppenheimer & Close sold 885 Moderna shares in Q3 2021, an estimated $207K.
Oppenheimer & Close first reported a position in Moderna in Q2 2021 and held it in 1 quarter.
Oppenheimer & Close's Moderna position peaked at $207K in Q2 2021.
1,140 funds tracked by Wall St. Rank held Moderna as of Q3 2021.

Based on Oppenheimer & Close's 13F filing for Q3 2021, filed 29 Oct 2021.